Irvington, NY, USA – MELA Sciences, Inc., a medical device company, announced the resignation of Richard I. Steinhart, SVP finance and chief financial officer and the appointment of Jeff O’Donnell as a director.[break]
Mr. Steinhart began serving as MELA Sciences’ Vice President, Finance, Chief Financial Officer, and Treasurer in April 2006, and Secretary in November 2006; in March 2012 he was promoted to Senior Vice President, Finance.
Before joining the Company, he spent 14 years as Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies.
Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart’s experience also includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, he served on the Board of Manhattan Pharmaceuticals, Inc., a biopharmaceutical company, and was Chairman of its Audit Committee.
Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant.
Rose Crane, MELA’s CEO, will handle the CFO responsibilities on an interim basis with the assistance of the company’s controller.
Mr. O’Donnell is Managing Director of BioStar Ventures, a venture capital firm specializing in early stage medical devices. Of particular relevance are his prior experience and relationships in medical dermatology gained as President and CEO of PhotoMedex, Inc., a medical device company, from 1999 through 2009.
Mr. O’Donnell’s industry experience also includes the formation of Embrella Cardiovascular, a medical device company, in 2007. He was named Chairman and CEO in 2009, and in 2011 the Company was sold to Edwards Lifesciences Corp..
From 1995 - January 3, 2014, Irvington, NY, USA – MELA Sciences, Inc., a medical device company, announced the resignation of Richard I. Steinhart, SVP finance and chief financial officer and the appointment of Jeff O’Donnell as a director.
Article continues below
break]
Mr. Steinhart began serving as MELA Sciences’ Vice President, Finance, Chief Financial Officer, and Treasurer in April 2006, and Secretary in November 2006; in March 2012 he was promoted to Senior Vice President, Finance.
Before joining the Company, he spent 14 years as Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies.
Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart’s experience also includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Until December 2011, he served on the Board of Manhattan Pharmaceuticals, Inc., a biopharmaceutical company, and was Chairman of its Audit Committee.
Mr. Steinhart began his career at Price Waterhouse, now known as PricewaterhouseCoopers. He holds BBA and MBA degrees from Pace University and is a Certified Public Accountant.
Rose Crane, MELA’s CEO, will handle the CFO responsibilities on an interim basis with the assistance of the company’s controller.
Mr. O’Donnell is Managing Director of BioStar Ventures, a venture capital firm specializing in early stage medical devices. Of particular relevance are his prior experience and relationships in medical dermatology gained as President and CEO of PhotoMedex, Inc., a medical device company, from 1999 through 2009.
Mr. O’Donnell’s industry experience also includes the formation of Embrella Cardiovascular, a medical device company, in 2007. He was named Chairman and CEO in 2009, and in 2011 the Company was sold to Edwards Lifesciences Corp..
From 1995-2000 Mr. O’Donnell was President, COO and then promoted to CEO of Cardiovascular Dynamics, Inc., an interventional cardiology company. He led the company from start-up, raised an IPO and created strategic alliances with Medtronic and Guidant Corporation. Cardiovascular Dynamics became Radiance Medical Systems, which was purchased by Endologix in 2000.
Mr. O’Donnell remained on the Endologix Board until 2012. Mr. O’Donnell is currently on the Boards of CD Diagnostics and BioSig Technology and serves as Executive Chairman of Trice Orthopedics, Inc. He holds a BS in Business Administration from LaSalle University, Philadelphia, PA. ■